Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$5.83
>-$0.01(-0.49%)
At close: 4:00 PM EST
$5.83
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$3.76 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$49.95M
Enterprise Value$8.65M
Total Cash (Recent Filing)$41.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
May 18, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding8,611,361
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-540.46
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$19.75Price Target Upside238.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patent ResolutionSettlement of endoxifen patent disputes with Intas and Jina removes a major legal overhang and preserves the company's ability to develop and commercialize Z-endoxifen across oncology, endocrine disorders, and Duchenne muscular dystrophy, increasing visibility around intellectual property protection.
Regulatory IncentivesRare pediatric disease designation for endoxifen combined with reauthorized priority review vouchers creates a potential path to expedited review and a transferable voucher that could enhance the program's commercial value if approval is achieved.
Scientific Rationale And Clinical SignalPeer-reviewed research describing how Z-endox may address inflammation, fibrosis, and mitochondrial dysfunction, along with prior favorable safety data and promising clinical signals, strengthens the scientific case for advancing into a Phase two program for Duchenne muscular dystrophy.
Bears Say
Capital And Dilution RiskSignificant share price decline and expectations of a need to raise capital increase the risk of equity dilution and potential further downward pressure on the stock.
Early-stage Program ValuationAnalyst assigns no value to the Duchenne muscular dystrophy program due to its preclinical status and a crowded development landscape, indicating limited near-term contribution from that program.
Forecast Risk AdjustmentsAnalyst applies substantial risk adjustments to commercial forecasts because clinical trial outcomes and the program's development stage create meaningful uncertainty for future revenues, weighing on valuation assumptions.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $3.76 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $49.95M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is May 18, 2026 which is in 10 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Mar 25, 2026. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$1.138 by -$0.052.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.99.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 8,611,361 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.19 in its last earnings report, missing expectations of -$1.138. Following the earnings report the stock price went down -13.1%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (238.77% Upside)
$19.75 (238.77% Upside)
Hedge Fund Trend
Increased
By 3.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.34%
12-Months-Change
Fundamentals
Return on Equity
-65.56%
Trailing 12-Months
Asset Growth
-37.72%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$19.75
▲(238.77% Upside)
Technical Analysis
Ownership Overview
52.53% Insiders
25.46% Mutual Funds
<0.01% Other Institutional Investors
18.03% Public Companies and
Individual Investors